What is Insight Molecular Diagnostics Days Payable?
Insight Molecular DiagnosticsIMDX -0.19%49 Days Payable is 11,162.02 as of Mar. 2026, which is 2528% above its 10-year median of 424.80. GuruFocus rates IMDX with a GF Score™ of 49/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Insight Molecular Diagnostics ranks better than 91.1% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's Days Payable distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's Days Payable falls into.
Insight Molecular Diagnostics Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insight Molecular Diagnostics (IMDX) has a Days Payable of 11,162.02 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Insight Molecular Diagnostics and its competitors. This is 2528% above median its historical median of 424.80. Over the past decade, Insight Molecular Diagnostics' Days Payable has ranged from 88.64 to 674.69. According to the industry distribution chart, Insight Molecular Diagnostics ranks #17 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 8.9%.
Is Insight Molecular Diagnostics' Days Payable too high?
Insight Molecular Diagnostics' current Days Payable of 11,162.02 is 2528% above median its 10-year median of 424.80. Over the past 10 years, this metric has ranged from a low of 88.64 to a high of 674.69. The Medical Diagnostics & Research industry median Days Payable is 68.87. Insight Molecular Diagnostics' value of 11,162.02 is 16107.4% above this industry median. Based on the distribution chart, Insight Molecular Diagnostics ranks #17 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' Days Payable compare to BDSX and XGN?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #17 out of 191 companies for Days Payable. This places Insight Molecular Diagnostics in the top 9% of its industry — outperforming the majority of peers. The industry median Days Payable is 68.87. Insight Molecular Diagnostics' value of 11,162.02 is 16107.4% above this benchmark. Historically, Insight Molecular Diagnostics' own Days Payable has ranged from 88.64 to 674.69 over the past decade. While the company's 10-year median is 424.80 vs. the industry median of 68.87, Insight Molecular Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insight Molecular Diagnostics's current Days Payable of 11,162.02 is 16107.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current Days Payable is 11,162.02, which is 2528% above median its own 10-year median of 424.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $5.42 — trading 330.2% above its estimated fair value. The current Days Payable is 11,162.02, which is 2528% above median its 10-year median of 424.80 and 16107.4% above the Medical Diagnostics & Research industry median of 68.87. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current Days Payable is 11,162.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.42 is trading 330.2% above its estimated GF Value™ of $1.26.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
Days Payable: 11,162.02 (2528% above median its 10-year median of 424.80)
GF Value™: $1.26 vs. price of $5.42 (330.2% above fair value)
Industry Position: 16107.4% above the Medical Diagnostics & Research median (#17 of 191)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
